Cancer Research
Excerpt from the Press Release: PHILADELPHIA and VANCOUVER, British Columbia, May 06, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to report it has received FDA clearance to initiate clinical evaluation of Bria-BRES+, its…
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging disease Results from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma Excerpt from the Press Release: SAN CARLOS, Calif.–(BUSINESS WIRE)–BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160;…
Renowned Brown University physician-scientist Eric M. Morrow, MD, PhD, to lead trailblazing initiative focused on accelerating discovery and improving care across the lifespan Excerpt from the Press Release: PHILADELPHIA, April 29, 2026 /PRNewswire/ — Penn Medicine and Children’s Hospital of Philadelphia (CHOP) today announced the appointment of Eric M. Morrow, MD, PhD, as the founding…
Excerpt from the Press Release: SAN FRANCISCO, April 29, 2026 (GLOBE NEWSWIRE) — Laguna Biotherapeutics, Inc. (Laguna), a clinical-stage biotechnology company focused on novel live bacterial therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application, granting a “safe to proceed” for its lead clinical candidate…
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., April 30, 2026 /PRNewswire/ — IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company, today announced that the U.S. Food and Drug Administration (FDA) has agreed to review its New Drug Application (NDA) for darovasertib in combination with crizotinib (darovasertib combination) for patients with first…
Primary endpoint (virologic response and ALT normalization) achieved in both dose arms at Week 24 -Favorable safety and tolerability profiles observed – Full results to be presented in a late-breaking poster presentation at EASL 2026 -Topline Phase 3 data from AZURE-1 and AZURE-4 expected in H2 2026 Excerpt from the Press Release: FOSTER CITY, Calif.–(BUSINESS…
Excerpt from the Press Release: BOSTON, April 27, 2026 (GLOBE NEWSWIRE) — Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that it met the key secondary endpoint of PFS and showed additional compelling results in the randomized COMPANION-002 study, which evaluated tovecimig plus paclitaxel versus paclitaxel alone…
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Excerpt from the Press Release: PRINCETON, N.J. & TOKYO & ZURICH–(BUSINESS WIRE)–Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced…
Excerpt from the Press Release: MUNICH & SAN FRANCISCO–(BUSINESS WIRE)–CatalYm today announced that the first patient has been dosed in the GDFATHER-HCC-01 trial (NCT07219459). The trial evaluates the company’s lead anti-GDF-15 antibody visugromab in combination with chemoimmunotherapy as a second-line (2L) treatment for patients with unresectable or metastatic hepatocellular carcinoma (HCC). The Phase 2b trial…
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., April 6, 2026 /PRNewswire/ — IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced that the first patient has been enrolled in its Phase 1 dose escalation trial evaluating IDE574, a potential first-in-class oral small molecule equipotent dual inhibitor of the lysine…